These findings are consistent with earlier reports showing that HMGB1 plays a crucial pathological role in inflammation-mediated kidney injury and diseases (55) and that therapeutic inhibition of HMGB1 by glycyrrhizin improves long-term recovery of patients with AKI (56). Here, HMGB1 is linked to acute kidney injury.